Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VCAR 33

Next Previous
Drug Profile

VCAR 33

Alternative Names: Anti-CD33 chimeric antigen receptor T-cell therapy - Vor Biopharma; VCAR-33; VCAR33ALLO; VCAR33AUTO

Latest Information Update: 07 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Cancer Institute (USA)
  • Developer Vor Biopharma
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia

Most Recent Events

  • 20 Mar 2025 Vor Bio anticipate initiation of the first trem-cel+VCAR33 Treatment System clinical trial in the second half of 2025
  • 03 Mar 2025 Efficacy data from phase I/II trial in Acute myeloid leukaemia were presented at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2024)
  • 07 Dec 2024 Pharmacodynamics data from preclinical study in Acute myeloid leukaemia were presented at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top